Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    " October 07, 2013":" November 06, 2013"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed The Safety and Immunogenicity of a Potential HIV Vaccine
Condition: HIV Infections
Intervention: Biological: CN54gp140 mixed with GLA-AF
2 Completed
Has Results
PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months
Condition: HIV Infection
Interventions: Other: Intervention 1: PK assessment while on Twice Daily Abacavir;   Other: Intervention 2: PK assessment while on Once Daily Abacavir
3 Withdrawn Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
Condition: HIV Infections
Intervention: Drug: Rilpivirine
4 Withdrawn Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env vaccine;   Biological: NYVAC Nat-B env vaccine;   Biological: DNA CON-S env vaccine;   Biological: NYVAC CON-S env vaccine;   Biological: DNA Mosaic env vaccine;   Biological: NYVAC Mosaic env vaccine;   Biological: Placebo;   Device: Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)
5 Withdrawn Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123;   Biological: NYVAC-HIV-PT1;   Biological: NYVAC-HIV-PT4;   Biological: AIDSVAX B/E®;   Biological: Placebo vaccine
6 Completed Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children
Condition: HIV Infection
Interventions: Drug: ABC Twice Daily;   Drug: ABC Once Daily;   Drug: 3TC Once Daily;   Drug: 3TC Twice Daily
7 Active, not recruiting Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Conditions: HIV;   HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: TAF;   Drug: Placebo to match TAF;   Drug: E/C/F/TAF;   Drug: Pre-existing ARV regimen;   Drug: ATV
8 Active, not recruiting Barbershop Talk: HIV Prevention for African American Heterosexual Men
Condition: HIV
Interventions: Behavioral: BTWB intervention;   Behavioral: Cancer prevention and screening
9 Completed Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
Condition: HIV-1 Infection
Interventions: Drug: Raltegravir;   Drug: Efavirenz
10 Recruiting Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Condition: HIV
Intervention: Drug: alendronate/vitamin D
11 Completed Feasibility of an Exercise Intervention
Condition: HIV
Intervention: Other: HOME-EX
12 Not yet recruiting Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth
Condition: HIV
Intervention: Behavioral: Motivational Enhancement Therapy (MET)
13 Completed Mother Infant Retention for Health: MIR4Health
Condition: HIV/AIDS
Intervention: Behavioral: Study Intervention for Retention (APFU)
14 Completed Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")
Conditions: HIV;   AIDS
Intervention: Behavioral: Neuropsychological testing
15 Completed A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04
Condition: HIV
Interventions: Drug: 1% vaginally applied tenofovir gel;   Drug: Tenofovir film- 10mg;   Drug: Tenofovir Film-40 mg;   Other: HEC Placebo Gel;   Other: Placebo Vaginal Film
16 Active, not recruiting Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.
Condition: HIV
Intervention: Drug: emtricitabine / tenofovir 200/300 mg
17 Unknown  Modified Directly Observed Antiretroviral Therapy
Condition: HIV
Intervention: Other: Home visits
18 Enrolling by invitation Botswana Combination Prevention Project
Condition: HIV
Interventions: Other: Combination Prevention;   Other: Enhanced Care
19 Active, not recruiting Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
Conditions: HIV;   HIV-associated Neurocognitive Disorder;   Neurotoxicity
Intervention: Drug: switch efavirenz (EFV) to raltegravir (RAL)
20 Active, not recruiting Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone
Condition: HIV+
Interventions: Drug: Oral naltrexone;   Drug: Naltrexone implant

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.